Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-08-13 15:03:00 UTC |
---|
Update Date | 2022-03-07 02:49:20 UTC |
---|
HMDB ID | HMDB0004242 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | 11-Dehydro-thromboxane B2 |
---|
Description | 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. Given its production in the allergic lung, antagonism of the 11-dehydro- thromboxane B2/CRTH2axis may be of therapeutic relevance. (PMID 14668348 )Thromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
---|
Structure | CCCCC[C@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O InChI=1S/C20H32O6/c1-2-3-6-9-15(21)12-13-18-16(17(22)14-20(25)26-18)10-7-4-5-8-11-19(23)24/h4,7,12-13,15-18,21-22H,2-3,5-6,8-11,14H2,1H3,(H,23,24)/b7-4+,13-12+/t15-,16-,17-,18+/m0/s1 |
---|
Synonyms | Value | Source |
---|
11-dehydro-Thromboxane | HMDB | 11-dehydro-TXB2 | HMDB, MeSH | 11-Dehydrothromboxane | HMDB | 11-Dehydrothromboxane b2 | HMDB, MeSH | 11-DehydroTXB2 | HMDB | 11-keto-Thromboxane | HMDB | 11-keto-Thromboxane b2 | MeSH, HMDB |
|
---|
Chemical Formula | C20H32O6 |
---|
Average Molecular Weight | 368.4645 |
---|
Monoisotopic Molecular Weight | 368.219888756 |
---|
IUPAC Name | (5E)-7-[(2R,3S,4S)-4-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-oxooxan-3-yl]hept-5-enoic acid |
---|
Traditional Name | (5E)-7-[(2R,3S,4S)-4-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-6-oxooxan-3-yl]hept-5-enoic acid |
---|
CAS Registry Number | 67910-12-7 |
---|
SMILES | CCCCC[C@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O |
---|
InChI Identifier | InChI=1S/C20H32O6/c1-2-3-6-9-15(21)12-13-18-16(17(22)14-20(25)26-18)10-7-4-5-8-11-19(23)24/h4,7,12-13,15-18,21-22H,2-3,5-6,8-11,14H2,1H3,(H,23,24)/b7-4+,13-12+/t15-,16-,17-,18+/m0/s1 |
---|
InChI Key | KJYIVXDPWBUJBQ-SOGWKEBJSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as thromboxanes. These are eicosanoids structurally characterized by the presence of a 6-member ether containing ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Thromboxanes |
---|
Alternative Parents | |
---|
Substituents | - Thromboxane
- Long-chain fatty acid
- Delta valerolactone
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Delta_valerolactone
- Unsaturated fatty acid
- Oxane
- Fatty acid
- Dicarboxylic acid or derivatives
- Secondary alcohol
- Lactone
- Carboxylic acid ester
- Oxacycle
- Organoheterocyclic compound
- Carboxylic acid derivative
- Carboxylic acid
- Hydrocarbon derivative
- Alcohol
- Carbonyl group
- Organic oxygen compound
- Organooxygen compound
- Organic oxide
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
11-Dehydro-thromboxane B2,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C | 2891.1 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O | 2844.7 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1OC(=O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C | 2859.7 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C | 2827.0 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2882.9 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,2TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C | 2824.0 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2815.0 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3114.7 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O | 3041.5 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1OC(=O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C | 3101.9 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3279.8 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3357.2 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,2TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C | 3275.3 | Semi standard non polar | 33892256 | 11-Dehydro-thromboxane B2,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1OC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1C/C=C/CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3502.7 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - 11-Dehydro-thromboxane B2 GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f6x-8694000000-b3e1575c156ad43560a4 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 11-Dehydro-thromboxane B2 GC-MS (3 TMS) - 70eV, Positive | splash10-01b9-3503590000-33e79e5366d8cf9dd7dd | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 11-Dehydro-thromboxane B2 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 11-Dehydro-thromboxane B2 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 10V, Positive-QTOF | splash10-0ue9-0029000000-14e5a0b6b8a0ad2b4202 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 20V, Positive-QTOF | splash10-0kh9-3179000000-f322c721c2db5ce99c1c | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 40V, Positive-QTOF | splash10-0l0m-9040000000-cd3172ac0337835ae861 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 10V, Negative-QTOF | splash10-00kb-0069000000-46a20251644a343285c0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 20V, Negative-QTOF | splash10-05bb-2197000000-44ea48cdcb64f0e36817 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 40V, Negative-QTOF | splash10-0a4i-9342000000-b6b00743b4251325d4d1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 10V, Positive-QTOF | splash10-0ue9-0019000000-a730bfd252e796a9a5eb | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 20V, Positive-QTOF | splash10-053u-9314000000-50e0714da1dd551fc405 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 40V, Positive-QTOF | splash10-067i-9300000000-fdf67ce1738087b8440c | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 10V, Negative-QTOF | splash10-014i-0009000000-03251a704cebdfe34808 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 20V, Negative-QTOF | splash10-066s-1049000000-afb6c183b0f042652b2f | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 11-Dehydro-thromboxane B2 40V, Negative-QTOF | splash10-000l-8692000000-ca867302a7906d2e249f | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
General References | - Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P: Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995 Sep;58(3):335-41. [PubMed:7554708 ]
- Clarke MW, Ward NC, Wu JH, Hodgson JM, Puddey IB, Croft KD: Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes. Am J Clin Nutr. 2006 Jan;83(1):95-102. [PubMed:16400056 ]
- De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, Davi G: Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost. 2003 Feb;1(2):250-6. [PubMed:12871497 ]
- Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999 Jan 19;99(2):224-9. [PubMed:9892587 ]
- Foulon I, Bachir D, Galacteros F, Maclouf J: Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. Arterioscler Thromb. 1993 Mar;13(3):421-6. [PubMed:8443146 ]
- Koudstaal PJ, Ciabattoni G, van Gijn J, Nieuwenhuis HK, de Groot PG, Sixma JJ, Patrono C: Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke. 1993 Feb;24(2):219-23. [PubMed:8421822 ]
- Rebuzzi AG, Natale A, Bianchi C, Albanese S, Lanza GA, Coppola E, Ciabattoni G: Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. Am Heart J. 1992 Mar;123(3):560-6. [PubMed:1539506 ]
- Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002 Jul 23;106(4):399-402. [PubMed:12135935 ]
- Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J: Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther. 1995 Oct;275(1):94-100. [PubMed:7562601 ]
- Morrow JD, Oates JA, Roberts LJ 2nd, Zackert WE, Mitchell TA, Lazarus G, Guzzo C: Increased formation of thromboxane in vivo in humans with mastocytosis. J Invest Dermatol. 1999 Jul;113(1):93-7. [PubMed:10417625 ]
- Maclouf J, Lellouche F, Martinuzzo M, Said P, Carreras LO: Increased production of platelet-derived thromboxane in patients with lupus anticoagulant. Agents Actions Suppl. 1992;37:27-33. [PubMed:1632300 ]
- Williams PC, Coffey MJ, Coles B, Sanchez S, Morrow JD, Cockcroft JR, Lewis MJ, O'Donnell VB: In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood. 2005 Oct 15;106(8):2737-43. Epub 2005 Jun 21. [PubMed:15972451 ]
- Bohm E, Sturm GJ, Weiglhofer I, Sandig H, Shichijo M, McNamee A, Pease JE, Kollroser M, Peskar BA, Heinemann A: 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem. 2004 Feb 27;279(9):7663-70. Epub 2003 Dec 10. [PubMed:14668348 ]
|
---|